[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"not-applicable---healthy-adult-participants\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:not-applicable---healthy-adult-participants":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100647884","phase-1-study-of-xmab412-in-healthy-participants-100647884",false,"NCT07713485","Study of XmAb412 in Healthy Participants","A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple-dose Escalation Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of XmAb412 in Healthy Adult Participants","Inclusion Criteria:\n\n* Age 18-55 years old\n* Must be in good health with no significant medical history\n* BMI 18-35 kg\u002Fm2\n* Contraceptive use consistent with local regulations\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Any physical condition that prohibits study completion\n* Known hypersensitivity to the trial intervention or any of its components\n* HIV, hepatitis B and hepatitis C positive\n* Clinically significant abnormal ECG\n* Use of other investigational products within 5 half lives from Screening\n* Blood or plasma donation within 60 days from Screening\n* Pregnant or breastfeeding\n\nOther protocol defined inclusion\u002Fexclusion criteria apply",true,"ALL","18 Years","55 Years",{"count":21,"type":22},128,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This Phase 1 Study will evaluate the safety, tolerability, pharmacokinectics and pharmacodynamics of XmAb412 in healthy adult participants",[28],"Not Applicable - Healthy Adult Participants",[30,31],"Inflammatory Bowel Disease","Health Adult Participants","RECRUITING","2026-07-31",{"date":35,"type":36},"2026-08-03","ACTUAL",{"date":38,"type":36},"2026-07-13",{"date":40,"type":22},"2028-03",{"name":42,"class":43},"Xencor, Inc.","INDUSTRY",2]